Loading...
Market
Story
FDA Approves Merck’s Keytruda with Chemotherapy for Advanced Mesothelioma
Sep 18, 2024, 10:48 AM
The FDA has approved Merck’s Keytruda (pembrolizumab) in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This FDA approval marks a significant advancement for patients suffering from this rare and aggressive form of lung cancer.
View original story
Similar markets
Below $5 billion • 25%
$5 - $5.49 billion • 25%
$5.5 - $5.99 billion • 25%
$6 billion or above • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%